May 7, 2007
 PDF Format |
Pacgen Announces Positive Results from Phase I/II Trial of Novel Anti-Fungal Drug
 listen to the Webcast |
April 17, 2007
PDF Format |
Pacgen
to Present at BioFinance 2007 |
March 30, 2007
PDF Format |
Pacgen
Builds on New Leadership and Updates Options Outstanding |
March 15, 2007
PDF Format |
Pacgen Completes Patient Recruitment for Phase I/II Trial of Novel Anti-Fungal Drug |
March 13, 2007
PDF Format |
Pacgen Appoints Robert DuFresne as President & CEO
listen
to the Webcast |
March 1, 2007
PDF Format |
Pacgen Reports Third Quarter Financial and Operating Results |
February 12, 2007
PDF Format |
Pacgen Appoints New Scientific Advisory Board Members |
December 7, 2006
PDF Format |
Pacgen Announces Closing of its Initial Public Offering |
August 30, 2006
PDF Format |
Pacgen Biopharmaceuticals Files for Initial Public Offering |
July 17, 2006
PDF Format |
Pacgen Biopharmaceuticals Names Dr. Alan Moore and Mr. Kevin McGarry to the Board of Directors |
April 20, 2006
PDF Format |
Pacgen
Biopharmaceuticals Appoints Christina Yip as Chief Financial
Officer |
April 12, 2006
PDF Format |
Pacgen
Biopharmaceuticals Acquires IL Therapeutics Inc. |
March 7, 2006
PDF Format |
Pacgen
Biopharmaceuticals Receives Approval for Phase I/II Clinical
Trial of PAC-113 for Oral Candidiasis |
October 24, 2005
PDF Format |
Pacgen
Biopharmaceuticals Contracts Vancouver-based Syreon Corporation
for its Phase I/II Clinical Trials of PAC-113 Mouthrinse
in HIV Seropositive Patients with Oral Candidiasis |
April 11, 2005
PDF Format |
Pacgen
Biopharmaceuticals Retains Dow Pharmaceutical Sciences
for PAC-113 Phase I/II Human Clinical Trials |
March 22, 2005
PDF Format |
Pacgen
Biopharmaceuticals In-Licenses Compounds for Oral Diseases
from Demegen
|
